Analytical Data
-
Gene name
Gba2
- Application
-
Alternative Names
(NLGase)(Beta-glucocerebrosidase 2)(Beta-glucosidase 2)(Bile acid beta-glucosidase GBA2)(Bile acid glucosyl transferase GBA2)(Cholesterol glucosyltransferase GBA2)(Cholesteryl-beta-glucosidase GBA2)(Glucosylceramidase 2)(Non-lysosomal cholesterol glycosyltransferase)(Non-lysosomal galactosylceramidase)(Non-lysosomal glycosylceramidase)
-
Species
Rat
-
Source
E. coli
-
Tag
C- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5M868
-
Expression Region
512-877aa
-
Molecular Weight
42.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Gba2, or glucocerebrosidase 2, is an important enzyme involved in lipid metabolism, specifically in the degradation of glucocerebrosides. Recent studies have highlighted its critical role in cellular homeostasis and its association with various diseases, including neurodegenerative disorders and lysosomal storage diseases. Research into Gba2 has been heightened due to its potential as a therapeutic target for conditions like Gaucher disease, where deficiencies in glucocerebrosidase lead to harmful accumulations of substrates. The recombinant production of Gba2 protein allows for in-depth biochemical characterization and facilitates the exploration of its structure-function relationships. By understanding the enzyme’s mechanism and interactions at a molecular level, scientists aim to develop novel treatments that can enhance enzymatic activity or stabilize the protein’s function. Furthermore, the study of Gba2 can provide insights into the broader implications of lysosomal dysfunction in human health. As such, the development of recombinant Gba2 offers valuable tools for both basic and applied research, opening up possibilities for innovative therapeutic strategies against a range of metabolic disorders.
